Drug profile · INN
loncastuximab tesirine
ZYNLONTA
loncastuximab tesirine (ZYNLONTA) is a b-lymphocyte antigen cd19 binding agent.
EMA: approved Antineoplastic and immunomodulating agents (L01) L01FX22
Patents linked 0
Pipeline programs 15
News articles 0
Drug details — loncastuximab tesirine
- Class
- Antineoplastic and immunomodulating agents (L01)
- Route
- —
- Patents
- 0
- Programs
- 15
- Data quality
- 0.83
Quick answer
loncastuximab tesirine (ZYNLONTA) is a b-lymphocyte antigen cd19 binding agent.
Key facts
INN loncastuximab tesirine
Brand ZYNLONTA
Mechanism B-lymphocyte antigen CD19 binding agent
Target B-lymphocyte antigen CD19
Therapeutic class Antineoplastic and immunomodulating agents (L01)
ATC code L01FX22
Mechanism of action
B-lymphocyte antigen CD19 binding agent
Primary target: B-lymphocyte antigen CD19
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is loncastuximab tesirine?
loncastuximab tesirine (ZYNLONTA) is a b-lymphocyte antigen cd19 binding agent.
What is the brand name for loncastuximab tesirine?
ZYNLONTA is a marketed brand name for loncastuximab tesirine. Check FDA Drugs@FDA for the current US label holder and prescribing information.